Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation in Acute Ischemic Stroke (SeeBCI)

22 septembre 2026 mis à jour par: Shandong Provincial Hospital

Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation Training in Patients With Acute Ischemic Stroke: The SeeBCI Study

This is a single-center, prospective, randomized, sham-controlled pilot clinical study designed to evaluate the efficacy, safety, and feasibility of early non-invasive electroencephalography-based brain-computer interface (EEG-BCI) rehabilitation training in patients with acute ischemic stroke.

Eligible participants are adults aged 18 to 80 years with acute ischemic stroke, unilateral upper extremity motor impairment on the dominant-hand side, a baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score of 10 to 50, and confirmed clinical stability 48 to 72 hours after stroke onset.

Participants will be randomly assigned in a 1:1 ratio to receive either real EEG-BCI training plus standard early rehabilitation or sham BCI training plus standard early rehabilitation. Both groups will receive 10 days of training, with two sessions per day and approximately 30 minutes per session.

The primary outcome is the change in FMA-UE score from baseline to 30 days after randomization. Secondary outcomes include changes in FMA-UE, Action Research Arm Test (ARAT), National Institutes of Health Stroke Scale (NIHSS), Modified Barthel Index (MBI), and modified Rankin Scale (mRS). Safety outcomes include symptomatic intracranial hemorrhage, any intracranial hemorrhage, neurological deterioration, seizures, falls, cardiovascular events, and training-related adverse events.

This pilot study aims to provide preliminary evidence regarding the feasibility, safety, and potential efficacy of early EEG-BCI rehabilitation after acute ischemic stroke and to inform the design of future multicenter randomized controlled trials.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

60

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age 18 to 80 years.
  2. Diagnosis of acute ischemic stroke.
  3. Stroke onset to randomization within 48 to 72 hours.
  4. Meets predefined clinical stability criteria before randomization.
  5. Unilateral upper extremity motor impairment on the dominant-hand side.
  6. Baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score between 10 and 50.
  7. Pre-stroke modified Rankin Scale (mRS) score ≤2.
  8. Written informed consent obtained from the participant or legally authorized representative.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Real EEG-BCI Training + Standard Early Rehabilitation

Participants will receive real electroencephalography-based brain-computer interface (EEG-BCI) training combined with standard early rehabilitation. The EEG-BCI training uses upper extremity motor imagery or motor attempt tasks with real-time decoding of motor intention and virtual hand feedback. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total).

Non-invasive EEG-based brain-computer interface training combined with standard early rehabilitation. The intervention includes EEG signal acquisition, motor intention decoding, and real-time virtual hand feedback. Participants perform upper extremity motor imagery or motor attempt tasks. Training is delivered twice daily for approximately 30 minutes per session for 10 consecutive days.

Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions.

Comparateur factice: Sham BCI Training + Standard Early Rehabilitation

Participants will receive sham BCI training combined with standard early rehabilitation. The sham procedure will match the real EEG-BCI training in appearance, frequency, duration, and workflow, but the feedback will not be generated by real-time EEG-based motor intention decoding. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total).

Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions.

Sham BCI training designed to maintain participant masking. The procedure matches real EEG-BCI training in device setup, training environment, frequency, duration, and workflow, but the feedback is not linked to the participant's real-time EEG motor intention decoding.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score From Baseline to Day 30
Délai: Baseline to Day 30 after randomization

The primary outcome is the change in FMA-UE score from baseline (T0) to 30 days after randomization. The FMA-UE evaluates upper extremity motor function after stroke, with scores ranging from 0 to 66. Higher scores indicate better upper extremity motor function. Change score is calculated as the FMA-UE score at Day 30 minus the baseline FMA-UE score.

Baseline to Day 30 after randomization

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score
Délai: Baseline, Day 10, Day 30, and Day 90

Upper extremity motor function will be assessed using the FMA-UE. The total score ranges from 0 to 66, with higher scores indicating better motor function.

Baseline, Day 10, Day 30, and Day 90
Action Research Arm Test (ARAT) Score
Délai: Baseline, Day 30, and Day 90

Upper extremity activity performance will be assessed using the ARAT. The total score ranges from 0 to 57, with higher scores indicating better upper limb functional ability.

Baseline, Day 30, and Day 90
National Institutes of Health Stroke Scale (NIHSS) Score
Délai: Baseline, Day 10, and Day 30

Neurological impairment will be assessed using the NIHSS. Scores range from 0 to 42, with higher scores indicating greater neurological deficit.

Baseline, Day 10, and Day 30
Modified Rankin Scale (mRS) Score
Délai: Day 90

Global functional outcome will be assessed using the modified Rankin Scale. Scores range from 0 to 6, with higher scores indicating greater disability.

Day 90
Modified Barthel Index (MBI) Score
Délai: Day 30 and Day 90

Activities of daily living will be assessed using the Modified Barthel Index. Higher scores indicate better functional independence.

Day 30 and Day 90

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Training Completion Rate
Délai: During the 10-day intervention period

Feasibility outcome defined as the proportion of completed EEG-BCI or sham BCI training sessions among the planned 20 sessions.

During the 10-day intervention period
Effective Training Duration
Délai: During the 10-day intervention period

Feasibility outcome defined as the cumulative duration of completed valid BCI training sessions during the intervention period.

During the 10-day intervention period
EEG Signal Quality and BCI Performance Metrics
Délai: During the 10-day intervention period

Feasibility outcome assessing EEG acquisition quality and available BCI performance metrics, including signal quality and classification accuracy when available.

During the 10-day intervention period
Follow-up completion rate
Délai: Through Day 90

Feasibility outcome defined as the proportion of randomized participants who complete scheduled outcome assessments through Day 90.

Through Day 90
Protocol deviation rate
Délai: From randomization through Day 90

Feasibility outcome defined as the proportion of participants with one or more protocol deviations.

From randomization through Day 90
Incidence of symptomatic intracranial hemorrhage
Délai: From baseline through Day 90

Safety outcome defined as the occurrence of symptomatic intracranial hemorrhage after randomization.

From baseline through Day 90
Incidence of any intracranial hemorrhage
Délai: From baseline through Day 90

Safety outcome defined as the occurrence of any type of intracranial hemorrhage after randomization.

From baseline through Day 90
Incidence of neurological deterioration
Délai: From baseline through Day 90

Safety outcome defined as clinically relevant neurological worsening after randomization, such as an increase in NIHSS score of 4 or more points without another clear explanation.

From baseline through Day 90
Incidence of seizures
Délai: From baseline through Day 90

Safety outcome defined as the occurrence of seizure events after randomization.

From baseline through Day 90
Incidence of Falls or Injuries
Délai: From baseline through Day 90

Safety outcome defined as the occurrence of falls during the study period.

From baseline through Day 90
Incidence of Cardiovascular and Vital Sign Events
Délai: From baseline through Day 90

Safety outcome defined as the occurrence of clinically relevant blood pressure instability or cardiac arrhythmia events during the study period.

From baseline through Day 90
Incidence of training-related discomfort
Délai: During the 10-day intervention period

Safety outcome defined as the occurrence of training-related discomfort, including fatigue, headache, dizziness, nausea, skin irritation, or other discomfort associated with the intervention.

During the 10-day intervention period
Incidence of serious adverse events
Délai: From baseline through Day 90

Safety outcome defined as the occurrence of serious adverse events (SAEs), including death, life-threatening events, hospitalization or prolongation of hospitalization, persistent or significant disability, or other medically important events.

From baseline through Day 90

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: QinJian Sun, MD, Shandong Provincial Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 octobre 2026

Achèvement primaire (Estimé)

1 octobre 2027

Achèvement de l'étude (Estimé)

1 décembre 2027

Dates d'inscription aux études

Première soumission

29 avril 2026

Première soumission répondant aux critères de contrôle qualité

8 mai 2026

Première publication (Réel)

13 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner